3Bryant HU.Mechanism of action and preclinical profile of raloxifene,a selective estrogen receptor modulation.Rev Endocr Metab Disord,2001,2(1):129-138.
4Snyder KR,Sparano N,Malinowski JM.Raloxifene hydrochloride.Am J Health Syst Pharm,2000,57(18):1669-1678.
5Johnston CC Jr,Bjarnason NH,Cohen FJ,et al.Long-term effects of raloxifene on bone mineral density,bone turnover,and serum lipid levels in early postmenopausal women:three-year data from 2 doubleblind,randomized,placebo-bontrolled.Intern Med,2000,160(22):3444-3450.
6Ettinger B,Black DM,Mitlak BH,et al.Reduction ofvertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene.JAMA,1999,282(7):637-645.
7Sambrook PN,Geusens P,Ribot C,et al.Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density:results of EFFECT(Efficacy of FOSAMAX versus EVISTA Comparison Trial)International.J Intern Med,2004,255(4):503-511.
8Barrett-Connor E,Mosca L,Collins P,et al.Effects of raloxifeme on cardiovascular events and breast cancer in postmenopausal women.N J Engl J Med,2006,355(2):125-137.
10Gozansky WS,Van Pelt RE,Jankowski CM,et al.Protection of bone mass by estrogens and raloxifene during exercise-induced weight loss.J Clin Endocrinol Metab,2005,90(1):52-59.
